$XBI $141.48 +0.5% 📈
Want to access our searchable database of 900 catalysts and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA -1% First patients dosed in phase 2 study evaluating COVID-19 booster vaccine candidate. source
Pipeline Updates
$BLUE +8% Updated findings that LentiGlobin unlikely the cause of AML in clinical study. They are initiating the process to discuss with regulators to resume clinical study. source
$MNOV +54% Announced partnership with BARDA to develop MN-166 as a countermeasure to chlorine gas-induced lung injury. source
$ACET +1% Initiated phase 1 trial of ADI-001 in NHL, data expected by end of year 2021. source
$BHVN -6% Nurtec ODT approved in Israel. source
$APLS +6% Phase 2 data of Peg in GA posted in two journals, the American Journal of Ophthalmology and Ophthalmology. source
$AVEO +89% Approval of FOTIVDA (tivo) for the treatment of adult patients with R/R advanced renal cell carcinoma. Commercial launch planned by end of March 2021. source
$KDMN +1% PDUFA target date for belumosudil for chronic graft-versus-host disease extended to 8/31/21. source